FDA approves CSL Behring's single-chain Afstyla for hemophilia A
The US Food and Drug Administration (FDA) has approved CSL Behring's Afstyla [Antihemophilic Factor (Recombinant) Single Chain] to treat adults and children with hemophilia A.
Afstyla, which is anticipated to be available in the US early this US summer, is indicated for routine prophylaxis to avoid or reduce the frequency of bleeding episodes; on-demand treatment and control of bleeding episodes; and the perioperative management of bleeding.
Click on this link for more information.
